Therapeutics for neurodegenerative diseases by targeting the gut microbiome: from bench to bedside

Translational Neurodegeneration, Journal Year: 2024, Volume and Issue: 13(1)

Published: Feb. 27, 2024

The aetiologies and origins of neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's (PD), amyotrophic lateral sclerosis (ALS) Huntington's (HD), are complex multifaceted. A growing body evidence suggests that the gut microbiome plays crucial roles in development progression diseases. Clinicians have come to realize therapeutics targeting potential halt This narrative review examines alterations AD, PD, ALS HD, highlighting close relationship between brain Processes mediate microbiome-brain communication including immunological, vagus nerve circulatory pathways, evaluated. Furthermore, we summarize for diseases modify its metabolites, diets, probiotics prebiotics, microbial antibacterials faecal transplantation. Finally, current challenges future directions discussed.

Language: Английский

---

The communication mechanism of the gut-brain axis and its effect on central nervous system diseases: A systematic review

Biomedicine & Pharmacotherapy, Journal Year: 2024, Volume and Issue: 178, P. 117207 - 117207

Published: July 26, 2024

Language: Английский

---

Harnessing Gut Microbiota for Biomimetic Innovations in Health and Biotechnology

Biomimetics, Journal Year: 2025, Volume and Issue: 10(2), P. 73 - 73

Published: Jan. 24, 2025

The gut microbiota is a complex and dynamic ecosystem that plays fundamental role in human health by regulating immunity, metabolism, the gut–brain axis. Beyond its critical physiological functions, it has emerged as rich source of inspiration for biomimetic innovations healthcare biotechnology. This review explores transformative potential microbiota-based biomimetics, focusing on key biological mechanisms such resilience, self-regulation, quorum sensing. These have inspired development innovative applications, including personalized probiotics, synbiotics, artificial microbiomes, bioinspired biosensors, bioremediation systems. Such technologies aim to emulate optimize intricate functions microbial ecosystems, addressing challenges environmental sustainability. integration advanced technologies, intelligence, bioengineering, multi-omics approaches, further accelerated biomimetics. tools enable precision therapies tailored individual profiles, enhance efficacy diagnostic systems, facilitate design environmentally sustainable solutions, waste-to-energy systems platforms. Emerging areas innovation, gut-on-chip models synthetic biology, offer unprecedented opportunities studying applying principles controlled environments. Despite these advancements, remain. replication complexity environments, ethical concerns regarding genetically engineered microorganisms, equitable access are hurdles must be addressed. underscores importance interdisciplinary collaboration public awareness overcoming barriers ensuring responsible solutions. By leveraging biomimetics represents promising frontier approach revolutionize therapeutic strategies, redefine tools, address global challenges, paving way more personalized, efficient, future medicine

Language: Английский

---

Fecal Microbiota Transplantation for Treatment of Parkinson Disease

JAMA Neurology, Journal Year: 2024, Volume and Issue: 81(9), P. 925 - 925

Published: July 29, 2024

Importance Dysbiosis has been robustly demonstrated in Parkinson disease (PD), and fecal microbiota transplantation (FMT) shown promising effects preclinical PD models. Objective To assess the safety symptomatic efficacy of colonic single-dose anaerobically prepared FMT. Design, Setting, Participants This was a double-blind, placebo-controlled, randomized clinical trial conducted between November 2020 June 2023 with follow-up period 12 months at 4 hospitals Finland. Patients aged 35 to 75 years Hoehn & Yahr stage 1-3 mild moderate symptom burden dysbiosis were included. Of 229 patients screened, 48 47 received intervention. One patient discontinued due worsening symptoms. Two further excluded before analysis 45 included intention-to-treat analysis. Intervention 2:1 ratio receive FMT or placebo via colonoscopy. Main Outcomes Measures The primary end point change Movement Disorder Society Unified Parkinson’s Disease Rating Scale parts I-III (part III off medication) 6 months. Safety assessed by recording adverse events (AEs). Results median (IQR) age 65 (52.5-70.0) group 66 (59.25-69.75) group; 9 (60.0%) 16 (53.3%) male group, respectively. outcome did not differ groups (0.97 points, 95% CI, −5.10 7.03, P = .75). Gastrointestinal AEs more frequent (16 [53%] vs 1 [7%]; .003). Secondary outcomes post hoc analyses showed stronger increase dopaminergic medication improvement certain motor nonmotor group. Microbiota changes pronounced after but differed donor. Nevertheless, status reversed frequently Conclusions Relevance safe offer clinically meaningful improvements. Further studies—for example, through modified approaches bowel cleansing—are warranted regarding specific impact donor composition conversion on as well needs PD. Trial Registration ClinicalTrials.gov Identifier: NCT04854291

Language: Английский

---

Gut Microbiota-Based Interventions for Parkinson’s Disease: Neuroprotective Mechanisms and Current Perspective

Probiotics and Antimicrobial Proteins, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 15, 2025

Language: Английский

---

Gut Microbiota as a Modifier of Huntington’s Disease Pathogenesis

Journal of Huntington s Disease, Journal Year: 2024, Volume and Issue: 13(2), P. 133 - 147

Published: May 10, 2024

Huntingtin (HTT) protein is expressed in most cell lineages, and the toxicity of mutant HTT multiple organs may contribute to neurological psychiatric symptoms observed Huntington's disease (HD). The proteostasis neurotoxicity are influenced by intracellular milieu responses environmental signals. Recent research has highlighted a prominent role gut microbiota brain immune system development, aging, progression disorders. Several studies suggest that might disrupt homeostasis (known as dysbiosis) impact pathogenesis HD. Dysbiosis been HD patients, animal models it coincides with aggregation, abnormal behaviors, reduced lifespan. This review article aims highlight potential pathways within microbiota-gut-immune-central nervous (CNS) axis. Understanding functions Wild-Type (WT) these associated networks elucidate novel pathogenic pathways, identify biomarkers peripheral therapeutic targets for

Language: Английский

---

Long-distance microbial mechanisms impacting cancer immunosurveillance

Immunity, Journal Year: 2024, Volume and Issue: 57(9), P. 2013 - 2029

Published: Aug. 15, 2024

Language: Английский

---

Disease-Modifying Therapies in Parkinson’s Disease

Neurologic Clinics, Journal Year: 2025, Volume and Issue: 43(2), P. 319 - 340

Published: Jan. 22, 2025

Language: Английский

---

Pharmacomicrobiomics: a new field contributing to optimizing drug therapy in Parkinson’s disease

Gut Microbes, Journal Year: 2025, Volume and Issue: 17(1)

Published: Jan. 28, 2025

Gut microbiota, which act as a determinant of pharmacokinetics, have long been overlooked. In recent years, growing body evidence indicates that the gut microbiota influence drug metabolism and efficacy. Conversely, drugs also exert substantial on function composition microbiota. Pharmacomicrobiomics, an emerging field focusing interplay provides potential foundation for making certain advances in personalized medicine. Understanding communication between antiparkinsonian is critical precise treatment Parkinson's disease. Here, we provide historical overview drugs. Moreover, discuss mechanistic insights into complex associations metabolism. addition, draw attention to microbiota-based biomarkers predicting efficacy examine current state-of-the-art knowledge strategies optimize therapy

Language: Английский

---

Unlocking the Code of Innovation: TRIZ Theory’s Blueprint for Precision Medicine Breakthroughs

Published: Jan. 1, 2025

Abstract Is there a fundamental “grand unified theory” that can systematically explain and predict innovations inventions in precision medicine? An approach is more than 70 years old may be able to answer this question. The Theory of Inventive Problem Solving (TRIZ) has revolutionized the space innovation problem-solving since its inception mid-twentieth century. Based on analysis hundreds thousands many fields, it extrapolated matrix contradictory patterns (problems) generalizable principles solve these problems. Research TRIZ culminates three findings: (1) Problems solutions are repeated across industries sciences. (2) Patterns technical evolution replicated (3) have scientific effects outside field which they were developed. This chapter suggests large parts Precision Medicine (PM) could interpreted as an application principles. Basically, PM seen implementation first principle, segmentation. For example, one most important applications PM, targeted cancer therapy, based segmentation tumors or tumor genetics analogous principle (segmentation). Another example single-cell multi-omics subtyping (patient, disease segmentation) for directing state-of-the-art therapeutics oncology other medical fields. Artificial intelligence machine learning playing increasing role process. question whether further point way get side therapies under control.

Language: Английский

---